Thrombolyttihoitoa

Thrombolyttihoitoa, also known as thrombolytic therapy or fibrinolysis, is a medical treatment used to dissolve blood clots that are blocking blood flow. These clots, called thrombi, can form in arteries or veins and lead to serious conditions such as heart attack (myocardial infarction), stroke (cerebrovascular accident), and deep vein thrombosis (DVT). The primary goal of thrombolytic therapy is to restore blood flow to the affected area quickly, thereby minimizing tissue damage and improving patient outcomes.

The therapy involves administering clot-busting drugs, often referred to as thrombolytics or fibrinolytics. These medications work by activating plasminogen, a protein naturally present in the body, which then converts into plasmin. Plasmin is an enzyme that breaks down fibrin, a protein that forms the meshwork of a blood clot. Common thrombolytic agents include alteplase (tPA), streptokinase, and urokinase.

Thrombolytic therapy is typically administered intravenously, with the medication infused directly into a vein. The dosage and duration of treatment depend on the specific condition being treated and the chosen drug. While highly effective, thrombolytic therapy carries risks, primarily an increased risk of bleeding. This is because the drugs not only break down pathological clots but can also interfere with the body's normal clotting mechanisms. Therefore, careful patient selection and monitoring are crucial. Contraindications for thrombolytic therapy include recent surgery, active bleeding, or a history of hemorrhagic stroke. Despite the risks, thrombolysis remains a vital treatment option for life-threatening thromboembolic events.